Duchenne muscular dystrophy (DMD) …

Michele Gatheridge MD

Neuromuscular Disorders

Updated 12.15.2025
Released 03.21.1994
Expires For CME 12.15.2028

Duchenne muscular dystrophy

Author: Michele Gatheridge MD

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Cite this article

Duchenne muscular dystrophy

In This Article

Quick Link

Introduction

Overview

Duchenne muscular dystrophy is a genetic neuromuscular disorder that affects approximately 1 in 5000 males (27). Proactive management with corticosteroids and early recognition of cardiac and respiratory pathophysiology have had a significant impact on improving the outcome of patients with Duchenne muscular dystrophy. It is an exciting time as more and more impactful genetic therapies (exon skipping and gene replacement therapy) show potential promise in treating patients with Duchenne muscular dystrophy.

Key points

	• Duchenne muscular dystrophy is a multisystem progressive genetic disease that primarily causes skeletal and cardiac muscle degeneration.
	• Dystrophin, a subsarcolemmal protein, is responsible for the severe pathology of muscle cells, and most therapeutic efforts are directed to provide functional dystrophin for the muscle tissue.
	• Survival is prolonged with corticosteroid use, ventilatory support, and multidisciplinary care.
	• Genetic treatments (exon skipping and gene replacement therapy) are now FDA approved, with continued trials in place to determine the full effect of these treatments.

Historical note and terminology

Duchenne muscular dystrophy is the most common muscular dystrophy. Studies published between 1850 and 1890 defined the course of the disorder in boys (95; 33; 40). The biochemical and genetic basis of Duchenne muscular dystrophy was elucidated in 1986 and 1987 in a series of studies that is considered a major early triumph of human molecular genetics (97; 49; 50; 66). Becker muscular dystrophy refers to a milder phenotype that is allelic to the same gene that causes Duchenne muscular dystrophy.

Clinical manifestations

Presentation and course

	• Duchenne muscular dystrophy is a multisystem X-linked recessive disease characterized by progressive weakness of skeletal muscle identified in early childhood.
	• Parents of boys with Duchenne muscular dystrophy note initial symptoms at a mean age of 2.5 years; however, a definite diagnosis is typically not made until about 5 years of age, indicating a significant delay in diagnosis.
	• Patients with Duchenne muscular dystrophy typically present to their pediatrician with proximal muscle weakness, elevated serum levels of creatine kinase, or, rarely, malignant hyperthermia after exposure to halothane anesthesia.
	• The rate of progression is variable, and disease severity does appear related to genetic mutation; however, all children show a decline in motor function, with a loss of ambulation and an eventual need for respiratory assistance.
	• Corticosteroids have been shown to improve muscle strength, pulmonary function, timed motor function, and delay loss of ambulation.

Presentation. Parents of boys with Duchenne muscular dystrophy note initial symptoms (typically difficulty walking/motor delay) at a mean age of 2.5 years, prompting evaluation by a primary care provider around 3.6 years of age; however, a definite diagnosis of Duchenne muscular dystrophy is typically not made until about 5 years of age, indicating a 2.5-year delay from identification of symptoms (123). Non-Caucasian and high poverty patients have been associated with later diagnosis. Specific genetic mutation subtypes may have later age of symptom onset and, thus, later diagnosis (26). In a family with a previously affected boy, the parents might suspect involvement of a second child earlier. Cognitive changes within the first year of life have been identified, indicating onset of symptoms is earlier than 2.5 years old (22). Early screening with serum creatine kinase in any boy who presents with developmental delay and specific motor test abnormality (ie, walking delay greater than 18 months) may help with earlier diagnosis (93).

Patients with Duchenne muscular dystrophy typically present to their pediatrician with proximal muscle weakness, elevated serum levels of creatine kinase, or, rarely, malignant hyperthermia after exposure to halothane anesthesia.

(1) Proximal muscle weakness. The most frequent presenting symptom is abnormal gait, delayed walking (3 to 6 months later than normal), frequent falling, difficulties getting up from the floor or climbing a stair, inability to jump or hop, and toe walking.

The abnormal gait is best characterized as a “waddle” and is due to early weakness of the glutei muscles (hip extensor and shock absorbers) when taking a step. Duchenne muscular dystrophy children bring their center of gravity to the other leg, repeating the same action with the next step, resulting in the typical waddle. The weakness of the hip extensors also leads to the forward tilt of the pelvis with compensatory lordosis, and frequently, to toe walking. The lordosis disappears in the sitting position. The tendency to walk on the toes precedes any contracture of the Achilles tendon and is due to a combination of weakness of the anterior tibialis muscle and an attempt to balance the center of gravity in the upright position.

The difficulty in getting up from the floor worsens with time. Normal children can do this in less than a second, usually jumping up from a prone to sitting and standing position. Children with Duchenne muscular dystrophy, like other children with proximal muscle weakness, take more than 2 seconds to perform this maneuver. Watching and timing this maneuver is useful in diagnosing and following the degree of muscle weakness. As the weakness progresses, children have to turn 45, then 90, and then 180 degrees to get up from a supine position on the floor. With mild weakness, patients may need to first place a hand on their knee to push themselves up. Eventually, the Duchenne boy goes to the full Gowers maneuver: he turns from supine to prone, then gets on his knees and elbows, extends knees and arms, moves the arms close to the trunk, and “marches up himself” with both hands on the legs until obtaining an upright position.

Enlargement of the muscles due to fat/fibrosis (pseudohypertrophy), especially of the calves, is an early and characteristic feature of Duchenne muscular dystrophy; this enlargement may become more prominent while the child is ambulating.

Pseudohypertrophy in Duchenne muscular dystrophy

Gastrocnemius muscle pseudohypertrophy in a Duchenne patient at 7 years of age. (Contributed by Dr. Gyula Acsadi.)

Although weakness of the arms is not a presenting symptom, mild proximal weakness might be found on early examination.

(2) Elevated serum levels of creatine kinase. Presymptomatic elevation of serum creatine kinase in children is a frequent presentation of Duchenne muscular dystrophy. Striking elevation of serum creatine kinase is present from birth (typically 100 to 200 times normal; normal is less than 200 IU/L). Along with elevated creatine kinase, transaminases (ALT and AST) are also elevated, which may mislead physicians to look for liver diseases.

(3) Malignant hyperthermia after exposure to halothane anesthesia. Malignant hyperthermia is a rare presentation of Duchenne muscular dystrophy. Patients undergoing surgery with halothane anesthesia can experience a malignant hyperthermic episode, with an increase in serum creatine kinase levels due to acute muscle necrosis. In a small number of young boys experiencing a malignant hyperthermic episode, serum creatine kinase levels remain dramatically elevated months after the episode. These patients should be investigated for muscular dystrophy.

Clinical course. The rate of deterioration is variable, and disease severity does appear related to genetic mutation; however, on quantitative assessment, all children show a downward trend (65; 06). The age of loss of ambulation varies between 7 and 13 years; however, any period of immobilization markedly accelerates this deterioration. Ambulation, physical therapy, and stretching exercises can minimize Achilles tendon contracture. However, once nonambulatory, patients tend to rapidly develop fixed skeletal deformities, progressive scoliosis, symptomatic respiratory weakness, and cardiac dysfunction. Untreated patients with Duchenne muscular dystrophy typically require noninvasive/invasive ventilation for survival by age 18 (35). Common cardiac findings are left ventricular dilation and depressed left ventricle ejection fraction. The exact mechanism of this is unclear but may be related to myocardial fibrosis (120).

Corticosteroids have been shown to improve muscle strength, pulmonary function, timed motor function, and delay cardiomyopathy onset and loss of ambulation (up to 3 years in some patients) (05; 38; 42). Nonambulatory patients receiving corticosteroids have improved percent-predicted forced vital capacity and upper extremity strength (23).

There is likely a relationship between neurodevelopment and Duchenne muscular dystrophy mutation, with a percentage of patients with Duchenne muscular dystrophy found to have speech delay (39%), learning difficulties (28%), inattentive-overactive behavior disorder (8%), and oppositional-defiant (5%) behavior disorder (122). Intellectual disability in these children is thought to be nonprogressive; however, severity of cognitive disability may vary depending on DMD gene mutation (29; 108).

Prognosis and complications

Duchenne muscular dystrophy is a lethal condition; however, survival has improved with advancements in medical care and implementation of multidisciplinary standards of care (35). Most early textbooks state that the majority of patients with Duchenne muscular dystrophy die by 20 years of age from respiratory insufficiency. Today, with multidisciplinary care and assisted ventilation, their lifespan can be doubled with an estimated life expectancy in ventilated patients of 29.9 years (68; 15). In patients utilizing assisted ventilation, cardiac dysfunction has become the major comorbidity (56). It remains unclear what the impact of new exon skipping and gene therapy treatments will have on survival.

Biological basis

Etiology and pathogenesis

	• Duchenne muscular dystrophy is caused by loss-of-function mutations of an extremely large gene, the Duchenne muscular dystrophy gene (DMD gene), located on the X-chromosome (Xp21).
	• Mutations on the DMD gene lead to a loss of function, resulting in markedly deficient or absent protein called dystrophin.

Duchenne muscular dystrophy is caused by mutations in the Duchenne muscular dystrophy gene (DMD gene) located on the X-chromosome (Xp21). Inheritance is X-linked recessive pattern. DMD gene occupies 2.5 million base pairs of DNA and is about 10 times larger than the next largest gene identified to date. The gene contains 79 exons of coding sequence, which together form the 14,000-base pair mRNA molecule (66; 110). Several mRNA and protein isoforms vary in size and tissue distribution (01). Deletions affecting one or more exons are present in 68% to 78% of boys with Duchenne muscular dystrophy; duplications are present in 11% (28; 12). The remaining boys have point mutations, small insertions, or small deletions. Deleted exons appear to be focused in mutation hotspots clustered in the region from exon 43-55 (60% to 65% of patients). In all mutations, the protein product of the gene, dystrophin, is absent or markedly deficient (49; 50; 13).

Dystrophin is localized to the plasma membrane of all myogenic cells, some classes of neurons, and in small amounts in other cell types (51).

Sarcolemmal dystrophin stain

Normal sarcolemmal dystrophin staining by a C-terminus primary dystrophin antibody. (Contributed by Dr. Gyula Acsadi.)

Deficiencies of other isoforms produced in liver tissue and other nonexcitable tissues do not seem to cause pathology (01). Dystrophin deficiency at the plasma membrane of muscle fibers disrupts the membrane cytoskeleton and leads to secondary loss of other components of the cytoskeleton, resulting in membrane instability and transient abnormal membrane flux (106; 31). The membrane leakage occurs from birth and causes the histopathologic features of active myopathy, yet muscle dysfunction is typically not detected until delayed walking. The chronic myopathy leads to fibrosis of muscle and, eventually, failure of regeneration. Abnormalities in dystrophin isoforms also play a role in brain abnormalities and cognitive disabilities (30; 121).

Dystrophin may play an important functional role in addition to its more evident structural role, though this is not completely understood.

Prevention

	• Duchenne muscular dystrophy is an inherited condition, and currently, the full clinical course cannot be prevented.
	• The disease has a high spontaneous mutation rate of about 30%.
	• Newborn screening for Duchenne muscular dystrophy is being piloted in some states and countries, with increased consideration as new disease-modifying drugs are developed and approved.

Duchenne muscular dystrophy is most often transmitted to male offspring by asymptomatic female carriers, as is typical of X-linked recessive conditions. Once a boy with Duchenne muscular dystrophy is identified, it is imperative to obtain molecular diagnosis for consideration of future mutation specific therapies. Genetic counseling should be offered to his immediate family members; mother's future sons may be at risk for Duchenne muscular dystrophy, and sisters of the proband may be carriers of the gene (16).

Genetic counseling of Duchenne families is complicated due to the high spontaneous mutation rate. For example, the mother of an isolated case of Duchenne muscular dystrophy has only a 66% chance of being a carrier, even though the mutation was carried in her egg to her affected son. Moreover, even if molecular diagnostics show that the mother is not a carrier of her affected son's mutation, there is still a recurrence risk because her ovaries may carry the mutation, even though her other tissues do not (gonadal mosaicism). Serum creatine kinase levels can be used as a first step to evaluate carrier status. A creatine kinase level above the upper limit of normal usually indicates a carrier; however, normal levels do not exclude carrier risk because only 70% of carriers will show elevated serum creatine kinase. Serum creatine kinase determinations in female carriers will normalize with advancing age, so measurements should be taken as soon as the affected boy is identified. Serum creatine kinase measurements are notoriously variable and can be affected by exercise and other activities not related to the disease.

Neonatal screening for Duchenne muscular dystrophy, based on elevated creatine kinase, has been piloted in the United States and is being implemented in other countries (58; 59). Identifying affected boys at birth can allow for earlier treatment with corticosteroids and initiation of new genetic treatments before the appearance of muscle fibrosis. Genetic counseling can also be provided to unsuspecting parents (114; 60).

Differential diagnosis

Confusing conditions

About 15% of patients with clinically suspected Duchenne muscular dystrophy and negative Duchenne muscular dystrophy genetic testing will have variants on next generation sequencing associated with other muscular dystrophies (57).

Sarcoglycanopathy. Rare cases of Duchenne-like muscular dystrophy that appear to have an autosomal recessive inheritance pattern have been reported, and about 20% to 40% of such patients have been found to have mutations of one of the four sarcoglycan genes (34).

Other childhood onset types of limb girdle muscular dystrophy. Typical symptoms include proximal muscle weakness with varying age of onset and progression.

Becker and intermediate dystrophinopathies. In the milder Becker muscular dystrophy, serum creatine kinase levels can approach those of Duchenne muscular dystrophy; however, they are frequently lower.

Other conditions to consider

X-linked vacuolar myopathy with excessive autophagy (XMEA). X-linked vacuolar myopathy with excessive autophagy is typically characterized by slow progression of proximal muscle weakness, which does not alter longevity. Muscle biopsy reveals excessive autophagic activity and exocytosis of the phagocytosed material. Onset is typically in childhood, though it can be variable.

Acquired inflammatory myopathies, dermatomyositis, polymyositis, viral myositis. Creatine kinase (CK) elevation may be similar to Duchenne muscular dystrophy; however, weakness typically progresses over weeks to months. Muscle pain and skin rash may also be present.

Late onset Pompe myopathy. An inherited autosomal recessive progressive metabolic myopathy that presents in the first year of life to adulthood. Muscle weakness is typically proximal and is commonly associated with respiratory insufficiency.

Associated or underlying disorders

Malignant hyperthermia. Malignant hyperthermia following use of halothane anesthesia does not necessarily indicate Duchenne muscular dystrophy. In patients having malignant hyperthermia as the primary disorder, serum creatine kinase levels will return to less than 10 times the upper limit of normal within 2 weeks after the episode. The small number of young boys whose serum creatine kinase values remain elevated months after a malignant hyperthermic episode should be investigated for Duchenne muscular dystrophy.

Diagnostic workup

	• Serum creatine kinase levels in patients with Duchenne muscular dystrophy are always elevated between 5000 and 150,000 IU/L (normal is less than 200 IU/L).
	• DNA test for confirmation of dystrophin gene mutation is now used as first-line diagnostic test after screening creatine kinase and is 95% sensitive, avoiding the need of a muscle biopsy in the majority of cases.
	• Additionally, early identification of female carriers and prenatal diagnosis should be offered to family members for pregnancy considerations and clinical evaluation.

In patients suspected of having Duchenne muscular dystrophy, a serum CK is an initial good screening marker. Serum creatine kinase levels in patients with Duchenne muscular dystrophy are always elevated between 5000 and 150,000 IU/L (normal is less than 200 IU/L). If a patient’s CK is elevated, genetic testing for Duchenne muscular dystrophy should be considered. Many different molecular diagnostic technologies are available to evaluate for various DMD gene mutations. Unless family history has identified a specific prior mutation, suspected patients should be evaluated initially for gene deletion/duplications. Large deletions (68% to 78% of patients) or large duplications (11%) can be assessed by PCR, multiplex ligation-dependent probe amplification, and chromosome microarray techniques (28; 12). Multiplex ligation-dependent probe amplification is currently the most widely applied technology due to convenience, high sensitivity, and cost (67; 37). Next generation sequencing, although advancing in ability to identify copy number variants, still has some limitations such as in identifying female carriers and duplications in males (37). If quantitative assays cannot completely characterize the mutation, sequencing of the coding Duchenne muscular dystrophy regions can evaluate for deletion endpoints, point mutations, and other small alterations (07; 69). Recommendations and algorithms for molecular testing have been updated by the Duchenne Muscular Dystrophy Care Consideration Working Group (69) and European Molecular Genetics Quality Network (37).

In patients testing negative for a DMD gene mutation, it is important to test the status of the dystrophin protein in a muscle biopsy (55). This is rarely done in patients with a confirmed genetic diagnosis. Absent dystrophin levels or levels less than 3% of normal are generally considered diagnostic of Duchenne muscular dystrophy (50). Levels of 12% to 18% usually indicate a milder phenotype such as Becker muscular dystrophy (50). It is important to note that all Duchenne dystrophy biopsies also show secondary deficiencies of many other proteins, such as sarcoglycans and dystroglycans (50).

Management

	• A comprehensive care guide detailing care throughout the five stages of Duchenne muscular dystrophy, from diagnosis to the late nonambulatory phase, may be reviewed in The Lancet Neurology (09). Despite published multidisciplinary guidelines, implementation of these care recommendations remains variable (04).
	• Glucocorticoids are recommended for the treatment of all Duchenne muscular dystrophy boys, both ambulatory and nonambulatory.
	• In recent years, exon skipping therapies and the first gene replacement therapy have been FDA approved, while awaiting confirmatory long-term treatment data.

Glucocorticoid treatment. Glucocorticoids are recommended for the treatment of all boys with Duchenne muscular dystrophy, both ambulatory and non-ambulatory (76). They improve muscle strength and pulmonary function, as well as reduce the need for scoliosis surgery and delay onset of cardiomyopathy (99; 38). When administered early in the disease process, prednisone 0.75 mg/kg/day, recommended by the current practice parameter set by the Academy of Neurology, has been shown to prolong ambulation for as long as 3 years (43; 99; 38; 76). Deflazacort (EMFLAZA), approved by the FDA in 2017 (ages 2 and older), has shown likely equal or superior effectiveness in improving muscle strength and delayed time to loss of ambulation when compared to prednisone (38; 42; 80; 83; 75; 81). In October 2023, vamorolone (AGAMREE), a novel dissociative steroid was approved by the FDA for use in ages 2 years and older. Vamorolone has shown a clinically significant benefit with fewer side effects compared to patients treated with corticosteroids (73; 45; 105). Continuing studies to evaluate vamorolone long term are needed and ongoing to determine optimal steroid treatment (NCT06564974).

Long-term glucocorticoid use and glucocorticoid use for nonambulatory patients should be considered. A study from MD STARnet showed that patients receiving long-term corticosteroid treatment (3.1 to 10.2 years) had prolonged ambulation by 2 years compared to untreated patients, and 1.2 years compared to the short-term treated group (0.25 to 3 years) (62). Glucocorticoids in nonambulatory patients have been shown to slow the decline of upper limb weakness, improve percent predicted forced vital capacity, and slow the decline of left ventricular ejection fraction, delaying the onset of cardiomyopathy (24; 103; 113). There remain unanswered questions regarding corticosteroids in infants, including what dose should be given and will early treatment lead to longer benefit (25).

Despite clear guidelines that steroids should be offered to patients with Duchenne muscular dystrophy, they are inconsistently or never prescribed (41; 44). Some patients start steroids but stop using them due to significant side effects; however, these side effects can be managed. Guidelines for treatment of endocrine complications due to prolonged glucocorticoid use, including obesity, obesity-related complications, and adrenal insufficiency are available (131; 14). Adjunct obesity pharmacotherapy is also being studied (39). Minimizing glucocorticoid-induced weight gain is important to maintain mobility and to reduce sleep-disordered breathing (131). Deflazacort may be associated with fewer side effects, less weight gain, and behavioral issues, whereas cataracts and bone health may appear worse compared to prednisone (08). Deflazacort is being explored for specific types of Duchenne muscular dystrophy mutations, in comparison to prednisone (117). Intermittent prednisone (10 days on/10 days off) over short term (6 months) has been shown to be noninferior to daily regiment with similar individual side effects (64; 46).

Nonsteroidal treatments to reduce inflammation. On March 21, 2024, the FDA approved the use of givinostat, the first nonsteroidal drug approved to treat all genetic variants of Duchenne muscular dystrophy. Givinostat is a histone decetylase (HDAC) inhibitor that reduces inflammation and loss of muscle. In a phase 3 trial among ambulant boys with Duchenne muscular dystrophy who had received systemic corticosteroids for at least 6 months, patients who received givinostat had a significantly slower decline on the four-stair climb than those who received placebo. The most significant side effects were a decrease in platelets and an increase in triglycerides. Full prescribing information should be reviewed; however, it is recommended that platelet counts and triglycerides be monitored prior to and during treatment. An ongoing study evaluating the long-term use of givinostat has shown that givinostat added to systemic corticosteroids delays functional decline compared to standard of care with corticosteroids alone (94; 79).

Bone health. Osteoporosis, resulting in low trauma vertebral and long bone fractures, is a complication in Duchenne muscular dystrophy due to the underlying myopathic process and glucocorticoid treatment. Vertebral fractures often are asymptomatic and can lead to chronic low back pain and spine deformity. Femur fractures can lead to early loss of ambulation and fat embolism syndrome (72). It is recommended to monitor for vertebral fractures with routine spinal radiographs at diagnosis and every 1 to 3 years, with more frequent monitoring in patients with Duchenne muscular dystrophy on glucocorticoids (72; 10; 128). For patients on glucocorticoids, the addition of growth hormone and testosterone has been shown to enhance long bone growth and may prolong time to next vertebral fracture (71; 78). In addition, serum 25-hydroxyvitamin D, serum calcium, spinal bone mineral density, and DEXA scan should be checked yearly, with other serum bone health markers checked at baseline and periodically thereafter. Intravenous bisphosphonates to maintain vertebral height, based on studies in osteogenesis imperfecta, are recommended for treatment of patients diagnosed with osteoporosis, defined as a child at risk for osteoporosis who sustains a long bone or vertebral fracture (129; 10; 128; 77). Overall, there remains variability in the management of osteoporosis to include starting bisphosphonate before fractures and the duration of treatment/management into adulthood (128; 77).

Joint contractures can compromise comfort and mobility. Detailed rehabilitation guidelines throughout all stages of Duchenne muscular dystrophy may be reviewed in the journal Pediatrics (19). Early in the disease, contracture of the ankles often leads to toe walking. Physical and occupational therapy assessments should be completed every 4 to 6 months, with frequent stretching of the involved tendons 4 to 6 days per week, and ankle-foot orthoses at night. Knee-ankle-foot orthoses can be considered for prevention of contracture in the late ambulatory or early nonambulatory stages (17; 19). Achilles tendon contractures generally begin to limit mobility by the end of the first decade, and surgical tendon lengthening can be considered in patients with significant ankle contraction and good proximal upper extremity strength (112; 10). Mobility should be encouraged as soon as possible after surgery.

Scoliosis is often seen during the first decade of life as the patient attempts to compensate for imbalance due to proximal leg weakness and becomes a primary concern when the patient uses a wheelchair. Wheelchair design and fitting are important for prevention or slowing of scoliosis. Scoliosis surgery has been shown to improve FVC for approximately 2 years postoperatively compared to nonsurgical treatment, delaying respiratory decline and, thus, extending survival in patients with Duchenne muscular dystrophy scoliosis (132; 70). Patients should be visually screened for scoliosis with every clinical exam. Spinal radiographs can be considered in obese patients where visualization may be more difficult (10). In patients with identified scoliosis, radiographs should be done every 6 to 12 months (10). A curve of more than 20 degrees in patients not treated by corticosteroids should trigger evaluation by a spinal surgeon due to fear of progression. In contrast, patients with spinal curvature on corticosteroids have a less predictable course so monitoring for progression is more reasonable (63; 10).

Pulmonary management. Proactive respiratory care has an important role in the management of patients with Duchenne muscular dystrophy, improving survival and quality of life (118; 35; 74; 126). As muscle weakness ensues, patients are at risk for several respiratory complications, including ineffective cough, pulmonary infections, obstructive sleep apnea, and respiratory failure (116). Other known complications of Duchenne muscular dystrophy, including cardiac, gastrointestinal, and orthopedic changes, likely also contribute to respiratory decline (10). Detailed guidelines for respiratory management in ambulatory and nonambulatory patients with Duchenne muscular dystrophy are available for review (10; 116). It is recommended that ambulatory boys, starting around age 5 or 6, have a measured forced vital capacity (FVC) annually to follow trajectory and accurately monitor for forced vital capacity decline in the absence of symptomatic dyspnea (10). Nonambulatory Duchenne muscular dystrophy boys should have pulmonary function testing twice a year, to include seated forced vital capacity, maximum inspiratory and expiratory pressures, peak cough flow, and blood oxygen saturation by pulse oximetry (10). Cough assist can be utilized when forced vital capacity is less than 50% predicted, cough peak flow is less than 270 liters per minute, or if cough becomes weak. Noninvasive ventilation (daytime and nocturnal) should be discussed when forced vital capacity is less than 50%, or in patients with abnormal sleep studies (10). Sleep studies should be completed yearly in patients with symptoms of sleep-disordered breathing (10). There is no clear evidence to favor 24-hour noninvasive ventilation versus tracheostomy in patients requiring assisted ventilation; however, in patients unable to use noninvasive respiratory assistance or in patients at risk for aspiration or who fail extubation three times, tracheostomy should be considered (10).

Cardiac management. Dilated cardiomyopathy due to dystrophin deficiency develops with variable severity after 6 years of age; therefore, it is recommended that patients have an annual screening cardiac assessment with electrocardiogram, as well as noninvasive imaging (echocardiogram or cardiac MRI). In patients who are symptomatic, imaging can be done more frequently based on cardiologist recommendation (10). Cardiac MRI measurement of “serial circumferential strain” appears to be more sensitive and reliable then “ejection fraction” calculation by echocardiogram, making MRI possibly a more useful tool for detection of early cardiomyopathy; however, this can be a difficult procedure for younger patients (6 to 7 years of age) (52; 47). Angiotensin-converting enzyme (ACE) inhibitor or beta-receptor blocker/diuretic should be used to prevent progression of cardiomyopathy. Treatment should be initiated by the first sign of cardiac decline (102; 36); however, further studies are being conducted to assess benefit of treatment in young, asymptomatic patients (younger than 10 years of age) (85; 10). There was no substantial difference in the improvement of cardiac function in patients with Duchenne muscular dystrophy treated with lisinopril (an ACE inhibitor) or losartan (an angiotensin receptor blocker) (03). In the late nonambulatory patients, it is important to monitor cardiac function and clinical manifestations of heart failure, and to optimize pulmonary function, with consideration of early initiation of noninvasive nocturnal ventilation, which has been shown to improve survival, though there may not be an effect on left ventricular dysfunction (85; 54).

Gastrointestinal management. Gastrointestinal dysmotility has been recognized in later stages of Duchenne muscular dystrophy due to disease progression and may affect any section of the gastrointestinal tract. Symptoms may include dysphagia, gastroesophageal reflux, delayed gastric emptying, and constipation. Current treatment is mainly symptomatic (119).

Multidisciplinary and long-term care. Management of a patient with Duchenne muscular dystrophy requires a multidisciplinary team approach, including multiple medical specialists outlined above, multidisciplinary rehabilitation teams (physical and occupational therapists, speech language pathologists, orthotists), psychologists, nutritionists, and social workers. As patients with Duchenne muscular dystrophy live well into their 30s, transition of care into adulthood, as well as psychosocial issues associated with chronic illness, become important management considerations (11; 124).

Genetic treatments. Considerable research efforts are underway to develop novel therapeutics for Duchenne muscular dystrophy based on knowledge of the molecular defect. This has led to encouraging new FDA-approved treatments.

Exon skipping. The use of antisense oligonucleotides to restore the Duchenne muscular dystrophy reading frame and produce functional dystrophin is a promising treatment of patients with particular deletions. There are currently four FDA-approved (under accelerated approval) exon skipping therapies targeting exon 51, 53, and 45 (Table 1). Eteplirsen is approved for use in patients who have mutations amenable to exon 51 skipping (about 13%). A phase 3 clinical trial showed treatment (96 weeks) with eteplirsen slows disease progression measured by the 6 meter walk test, and annual change in FVC percentage predicted, with a favorable safety profile (86; 02; 61; 84; 53). Golodirsen (Vyondys) and viltolarsen (Viltepso) target 53 skippable mutations. Long-term phase 1/2 data for golodirsen have shown favorable safety data and suggestion of functional benefit to be further explored in future studies (115). In a phase 2 clinical trial over 4 years, viltolarsen (Viltepso) treated patients showed stabilization of motor function over the first two years of treatment and then significant slowing of disease progression in the following two years compared to controls. There were mild to moderate adverse events, without drug discontinuation (21). Finally, casimersen for exon 45 skipping has shown increased dystrophin production in patients and is proceeding with phase 3 data (127). Other exon skipping molecules in phase II clinical trials include WVE-N531 (WAVE Life Sciences), and AAOC 1044 (Avidity Biosciences). AAOC 1044 skips exon 44, which received FDA fast track designation based on promising early clinical trial results (130).

Table 1. FDA-Approved Exon Skipping Therapies

Chemical	Drug	Other name	Sponsor	Target Exon
Phosphorodiamidate Morpholino Oligomer (PMO)	Eteplirsen	Exondys 51, AVI-4658	Sarepta Therapeutics	Exon 51
	Golodirsen	Vyondys 53, SRP405	Sarepta Therapeutics	Exon 53
	Viltolarsen	Viltepso, NCNP-01, NS-065	NS Pharma	Exon 53
	Casimersen	AMONDY S45, SRP4045	Sarepta Therapeutics	Exon 45

Gene therapy. Gene replacement strategies have the ability to treat the majority of Duchenne muscular dystrophy mutations. Systemic delivery of “naked” DNA has been achieved and has paved the way for long-awaited clinical trials (134; 135). There are multiple gene therapy trials utilizing various methods for delivery of dystrophin in clinical trials. ELEVIDYS is currently FDA approved, under accelerated approval, for use in select patients (Table 2).

ELEVIDYS. Delandistrogene moxeparvovec (SRP-9001) is FDA approved for ambulatory Duchenne muscular dystrophy patients aged 4 years and older with a confirmed DMD gene mutation and has received accelerated approval for nonambulatory patients of the same age. Functional improvements were seen through 4 years of use in patients enrolled in initial trials, with a mean age of 5.1 years at administration (90). In phase II trials of 4- to 8-year-old Duchenne muscular dystrophy patients, ELEVIDYS produced robust dystrophin expression with positive functional improvement, up to 2 years without serious adverse events (89; 91). Results from part one of the phase 3 trial (EMBARK study) did not lead to significant improvement in the primary endpoint, North Star Ambulatory Assessment (NSAA), at week 52. Some secondary endpoints, time to rise and 10-meter walk, favored treatment; however, no statistical significance was identified (87). Preliminary results from part 2 of the study revealed that the patients treated in part 1 at 64 weeks continued to show some divergence from the natural history of Duchenne muscular dystrophy and that the crossover-treated patients who received placebo for 52 weeks in part 1 and were then treated with ELEVIDYS in part 2 did show an increase in the NSAA at 52 weeks, as well as improvement in secondary endpoints (Study SRP-9001-301). A phase 1 study (ENDEAVOR) using commercial grade delandistrogene moxeparvovec is currently enrolling (NCT04626674). At 1 year, patients demonstrated stabilized or improved North Star Ambulatory Assessment total scores (133). ELEVIDYS is contraindicated in patients with any deletion in exon 8 or 9 due to risk of an immune-mediated myositis reaction. Recommendations for pre- and post-infusion monitoring have been published (88).

Table 2. FDA-Approved Gene Replacement Therapies

Brand Name	Generic	Genetic Critera	Dosing
ELEVIDYS	Delandistrogene moxeparvovec	Contraindicated for deletions of exon 8 and 9	1 time IV infusion

Other gene therapy clinical trials.

INSPIRE DUCHENNE. The INSPIRE DUCHENNE clinical trial using SGT-003, a microdystrophin transgene with a novel capsid, is recruiting. This is a phase I/II trial to evaluate the safety and tolerability of SGT-003 in various age groups (NCT06138639). A phase I/II trial to assess the safety and tolerability of solid biosciences SGT-001 (initial capsid) in adolescents with Duchenne muscular dystrophy is ongoing. Two-year data have shown sustained expression of functional dystrophin. Patients receiving the 2E14 vg/kg dose have also maintained motor function compared to natural history controls during this time period (32).

AFFINITY DUCHENNE. Phase I/II/III study of RGX-202, utilizing microdystrophin and AAV8 (NCT05693142).

Stop codon suppression. An oral delivery of ataluren, (Translarna), which promotes nonsense read through, has been shown to be well tolerated and associated with slowed disease progression, including respiratory decline and delayed loss of ambulation up to 2.2 years (18; 92; 82). Ataluren has been conditionally approved by the European Medicines Agency and is being investigated in the United States (100).

Gene editing utilizing CRISPR (clustered regularly interspaced short palindromic repeats). Gene editing for Duchenne muscular dystrophy is aimed at restoring the gene reading frame and producing some functional dystrophin. There has been promise using the CRISPR/Cas9 system to target mutated exons and perform a variety of mechanisms to knock-in/edit/skip such mutations, producing functional dystrophin in the mdx mice and dog. Most studies focus on the exon region of 45-55 or 21-23. Challenges with delivery, off-target mutagenesis, and evaluation of long-term effects exist. Additionally, there is a limitation to the length of the template and, thus, it is unlikely this method can be used for large DMD deletion mutations. Further development is needed prior to clinical trial (20).

Special considerations

Pregnancy

In female carriers either manifesting Duchenne muscular dystrophy or not, there is no reported increased risk during pregnancy to either the mother or child.

Anesthesia

Patients are at increased risk of malignant hyperthermia during exposure to halothane anesthesia.

COVID-19

Consensus guidelines for the care of patients with Duchenne muscular dystrophy during the COVID-19 pandemic have been published. Recommendations include continuing current corticosteroid regiments with potential dose adjustments should they become ill to prevent adrenal insufficiency and consideration of stress dose steroids in the setting of acute illness or hospitalization. Exon-skipping agents are encouraged to be continued. The risks and benefits of receiving these infusions during a pandemic should be discussed with the patient’s neurologist. It is recommended that angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prophylaxis or treatment of cardiomyopathy should be continued. Those with chronic respiratory insufficiency should be treated in collaboration with pulmonary or anesthesiology specialists and should not receive supplemental oxygen without ventilatory support. Finally, hydroxychloroquine has uncertain benefit and may cause skeletal or cardiac muscle damage and, thus, should not be prescribed for this patient population (125).

Based on a small study of children with neuromuscular conditions and documented SARS-CoV-2 infection (n=29 with five Duchenne muscular dystrophy/bone mineral density subjects), 89% of patients were asymptomatic or had mild symptoms to include mild upper respiratory symptoms and fever. Ten percent of patients had moderate symptoms to include mild respiratory distress without respiratory decline (101). In a separate review of seven adults Duchenne muscular dystrophy and SARS-CoV-2, there were no patients who developed moderate to severe symptoms, and all patients with mild symptoms recovered without complication or hospitalization (107). These results indicate there may be a protective role of young age, which may outweigh neuromuscular risk factors to include reduced respiratory capacity. These findings may also support that the SARS CoV-2 variants, known at the time of this publication, may not be more life threatening for this population than other respiratory viruses.

References

01: Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet 1993;3:283-91. PMID 7981747
02: Alfano LN, Charlston JS, Connolly AM, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (Baltimore) 2019;98(26):e15858. PMID 31261494
03: Allen HD, Flanigan KM, Thrush PT, et al. A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in Duchenne muscular dystrophy. PLoS Curr 2013;5. PMID 24459612
04: Andrews JG, Conway K, Westfield C, et al. Implementation of Duchenne muscular dystrophy care considerations. Pediatrics 2018;142(1). PMID 29925575
05: Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone/prednisolone and deflazacort regiments in the CINRG Duchenne Natural History Study. Neurology 2015;85(12):1048-55. PMID 26311750
06: Bello L, Morgenroth LP, Gordish-Dressman H, et al. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology 2016a;87(4):401-9. PMID 27343068
07: Bello L, Pegoraro E. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy. Acta Myol 2016b;35(3):122-7. PMID 28484312
08: Biggar WD, Skalsky A, McDonald CM. Comparing deflazacort and prednisone in Duchenne muscular dystrophy. J Neuromuscul Dis 2022;9(4):463-76. PMID 35723111
09: Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018a;17(3):251-67.** PMID 29395989
10: Birnkrant DJ, Bushby KM, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018b;17(4):347-61.** PMID 29395990
11: Birnkrant DJ, Bushby KM, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol 2018c;17(5):445-55.** PMID 29398641
12: Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 2015;36(4):395-402. PMID 25604253
13: Bonilla E, Samitt CE, Miranda AF, et al. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 1988;54:447-52. PMID 3042151
14: Bowden SA, Connolly AM, Kinnett K, Zeitler PS. Management of adrenal insufficiency risk After long-term systemic glucocorticoid therapy in Duchenne muscular dystrophy: clinical practice recommendations. J Neuromuscul Dis 2019:6(1):31-41. PMID 30614808
15: Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in Duchenne muscular dystrophy. Reproduced individual patient data meta-analysis. Neurology 2021;97(23):e2304-14. PMID 34645707
16: Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010a;9(1):77-93. PMID 19945914
17: Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010b;9(2):177-89. PMID 19945914
18: Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014;50(4):477-87. PMID 25042182
19: Case LE, Apkon SD, Eagle M, et al. Rehabilitation management of the patient with Duchenne muscular dystrophy. Pediatrics 2018;142(Suppl 2):S17-33. PMID 30275246
20: Choi E, Koo T. CRISPR technologies for the treatment of Duchenne muscular dystrophy. Mol Ther 2021;29(11):3179-91. PMID 33823301
21: Clemens PR, Rao VK, Connolly AM, et al. Efficacy and safety of viltolarsen in boys with Duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study. J Neuromuscul Dis 2023;10(3):439-47. PMID 37005891
22: Connolly AM, Florence JM, Cradock MM, et al. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscul Disord 2013;23(7):529-39. PMID 23726376
23: Connolly AM, Florence JM, Zaidman CM, et al. Outcome reliability in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up. Muscle Nerve 2016;54(4):681-9. PMID 26930423
24: Connolly AM, Malkus EC, Mendell JR, et al. Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy. Muscle Nerve 2015;51(4):522-32. PMID 25056178
25: Connolly AM, Ziadman CM, Golumbek PT, et al. Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle Nerve 2019;59(6):650-7. PMID 30706490
26: Counterman KJ, Furlong P, Wang RT, Martin AS. Delays in diagnosis of Duchenne muscular dystrophy: an evaluation of genotypic and sociodemographic factors. Muscle Nerve 2020;61(1):36-43. PMID 31573675
27: Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: an updated systemic review and meta analysis. Orphanet J Rare Dis 2020;15(1):141. PMID 32503598
28: Cunniff C, Andrews J, Meaney FJ, et al. Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol 2009;24(4):425-30. PMID 19074751
29: D’Angelo MG, Lorusso ML, Civati F, et al. Neurocognitive profiles in Duchenne muscular dystrophy and gene mutation site. Pediatr Neurol 2011;45(5):292-99. PMID 22000308
30: Daoud F, Angeard N, Demerre B, et al. Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum Mol Genet 2009;18(20):3779-94. PMID 19602481
31: Draviam R, Billington L, Senchak A, Hoffman EP, Watkins SC. Confocal analysis of the dystrophin protein complex in muscular dystrophy. Muscle Nerve 2001;24(2):262-72. PMID 11180210
32: Dreghici RD, Redican S, Lawrence J. FP.28 IGNITE DMD phase I/II study of SGT-001 microdystrophin gene therapy for DMD: Long-term outcomes and expression update. Neuromuscular Disorders. Neuromuscul Dis 2022;32(supplement 1):S98.
33: Duchenne GB. Recherches sur la paralysie musculaire pseudo-hypertrophique ou paralysie myosclerosique. Arch Gen Med 1868;11:5,178,305,421,552.
34: Duggan DJ, Gorospe JR, Fanin M, et al. Mutations in the sarcoglycan genes in myopathy patients. N Engl J Med 1997;336:618-24. PMID 9032047
35: Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 2007;17(6):470-5. PMID 17490881
36: El-Aloul B, Altamirano-Diaz L, Zapata-Aldana E, et al. Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: a systemic review. Neuromuscul Disord 2017;27(1):4-14. PMID 27815032
37: Fratter C, Dalgleish R, Allen SK, et al. EMQN best practice guidelines for genetic testing in dystrophinopathies. Eur J Hum Genet 2020;28(9):1141-59. PMID 32424326
38: Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86(5):465-72. PMID 26833937
39: Goldman V, Ryabets-Lienhard A, Howard L, et al. Obesity management in youth with Duchenne muscular dystrophy: a review of metformin and alternative pharmacotherapies. Child Obes 2025;21(2):103-12. PMID 39392010
40: Gowers WR. A manual of diseases of the nervous system. Vol. 1. London: Churchill, 1886:386-402.
41: Griggs RC, Herr BE, Reha A, et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 2013;48(1):27-31. PMID 23483675
42: Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology 2016;87(20):2123-31. PMID 27566742
43: Griggs RC, Moxley RT, Mendell JR, et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993;43(Pt 1):520-7. PMID 8450994
44: Guglieri M, Bushby K, McDermott MP, et al. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemp Clin Trials 2017;58:34-9. PMID 28450193
45: Guglieri M, Bushby K, McDermott MP, et al. Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA 2022a;327(15):1456-8. PMID 35381069
46: Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and safety of Vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol 2022b;79(10):1005-14. PMID 36036925
47: Hagenbuch SC, Gottliebson WM, Wansapura J, et al. Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. Am J Cardiol 2010;105(10):1451-5. PMID 20451693
48: Hoffman EP, Arahata K, Minetti C, et al. Dystrophinopathy in isolated cases of myopathy in females. Neurology 1992;42:967-75. PMID 1579251
49: Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-28. PMID 3319190
50: Hoffman EP, Fischbeck KH, Brown RH, et al. Dystrophin characterization in muscle biopsies from Duchenne and Becker muscular dystrophy patients. N Engl J Med 1988a;318:1363-8. PMID 3285207
51: Hoffman EP, Hudecki M, Rosenberg P, Pollina C, Kunkel LM. Cell and fiber-type distribution of dystrophin. Neuron 1988b;1:411-20. PMID 3078411
52: Hor KN, Wansapura J, Markham LW, et al. Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol 2009;53(14):1204-10. PMID 19341862
53: Iff J, Gerrits C, Zhong Y, et al. Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy. Muscle Nerve 2022;66(3):262-9. PMID 35715998
54: James KA, Gralla J, Ridall LA, et al. Left ventricular dysunction in Duchenne muscular dystrophy. Cardiol Young 2020;30(2):171-6. PMID 31964455
55: Jones HF, Bryen SJ, Waddell LB, et al. Importance of muscle biopsy to establish pathogenicity of DMD missense and splice variants. Neuromuscul Disord 2019;29(12):913-9. PMID 31706698
56: Kamdar F, Garry DJ. Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol 2016;67(21):2533-46. PMID 27230049
57: Karthikeyan P, Kumar S, Khanna-Gupta A, et al. In a cohort of 961 clinically suspected Duchenne muscular dystrophy patients, 105 were diagnosed to have other muscular dystrophies (OMDs), with LGMD2E (variant SGCB c.544A>C) being the most common. Mol Genet Genomic Med 2024;12(11):e2123. PMID 39548682
58: Ke Q, Zhao ZY, Griggs R, et al. Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment. World J Pediatr 2017;13(3):197-201. PMID 28466241
59: Ke Q, Zhao ZY, Mendell JR, et al. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy. World J Pediatr 2019;15(3):219-22. PMID 30904991
60: Kemper AR, Lam WKK, Ojodu J, et al. Evidence regarding Duchenne muscular dystrophy newborn screening. Pediatrics 2025. [Epub ahead of print] PMID 40790238
61: Khan N, Eliopoulous H, Han L, et al. Eteplirsen treatment attenuates respiratory decline in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. J Neuromuscul Dis 2019;6(2):213-25. PMID 30856119
62: Kim S, Campbell KA, Fox DJ, Matthews DJ, Valdez R, MD STARnet. Corticosteroid treatments in males with Duchenne Muscular Dystrophy: treatment duration and time to loss of ambulation. J Child Neurol 2015;30(10):1275-80. PMID 25414237
63: King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007;68(19):1607-13. PMID 17485648
64: Kochar GS, Sondhi V, Kabra SK, Yadav SL, Dwivedi SN, Gulati S. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial. Muscle Nerve 2022;65(1):60-6. PMID 34617309
65: Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989;45(4):498-506. PMID 2491009
66: Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-17. PMID 3607877
67: Lalic T, Vossen RHAM, Coffa J, et al. Deletion and duplication screening in the DMD gene using MLPA. Our J Hum Genet 2005;13(11):1231-4. PMID 16030524
68: Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmuller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta analysis. Eur J Epidemiol 2020;359(7):643-53. PMID 32107739
69: Leigh F, Ferlini A, Biggar D, et al. Neurology care, diagnostics, and emerging therapies of the patient with Duchenne muscular dystrophy. Pediatrics 2018;142(Suppl 2):S5-S16.** PMID 30275245
70: Liang H, Shao Z, Shi Y, Wang X. Comparison of surgical and non-surgical treatment for scoliosis in Duchenne muscular dystrophy: a systemic review and meta-analysis. Arch Orthop Trauma Surg 2025;145(1):219. PMID 40167615
71: Loscalzo E, See J, Bharill S, et al. Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids. Osteoporos Int 2024;35(2):327-8. PMID 37872346
72: Ma J, McMillan HJ, Karaguzel G, et al. The time to and determinants of first fracture in boys with Duchenne muscular dystrophy. Osteoporos Int 2017;28(2):597-608. PMID 27774565
73: Mah ML, Cripe L, Slawinski MK, et al. Duchenne and Becker muscular dystrophy carriers: evidence of cardiomyopathy by exercise and cardiac MRI testing. Int J Cardiol 2020;316:257-65. PMID 32473283
74: Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008;93(11):986-90. PMID 18667451
75: Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong B. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single large care center. J Comp Eff Res 2020;9(3):177-89. PMID 31922454
76: Matthews E, Brassington R, Kunter T, Jichi F, Manzur AY. Corticosteorids for the treatment of Duchenne muscular dystrophy. Cochrane Databse Syst Rev 2016;(5):CD003725.** PMID 27149418
77: McCarrison S, Abdelrahman S, Davies JH, et al. The use of bisphosphonate and testosterone in young people with Duchenne muscular dystrophy: an international clinician survey. J Pediatr Endocrinol Metab 2025;38(8):807-14. PMID 40270468
78: McCauley C, Smillie R, Dunne J, et al. Testosterone in Duchenne muscular dystrophy: effects on puberty and growth. J Pediatr Endocrinol Metab 2025;38(10):1022-32. PMID 40966753
79: McDonald CM, Guglieri M, Vucinic D, et al. Long-term evaluation of givinostat in Duchenne muscular dystrophy, and natural history comparisons. Ann Cain Trans Neurol 2025;12(11):2335-48. PMID 40830818
80: McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 2018;391(10119):451-61. PMID 29174484
81: McDonald CM, Marden JR, Shieh PB, et al. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient ate and functional status. J Comp Eff Res 2023;12(4):e220190. PMID 36749302
82: McDonald CM, Muntoni F, Penematsa V, et al. Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. J Comp Eff Res 2022;11(3):139-55. PMID 34791888
83: McDonald CM, Sajeev G, Yao Z, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve 2020;61(1):26-35. PMID 31599456
84: McDonald CM, Shieh PB, Abdel-Hamid HZ, et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J Neuromuscular Dis 2021;8(6):989-1001. PMID 34120909
85: McNally EM, Kaltman JR, Benson DW, et al. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation 2015;131(18):1590-8. PMID 25940966
86: Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 2016;79(2):257-71. PMID 26573217
87: Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the Embark phase 3 randomized trial. Nat Med 2025;31(1):332-41. PMID 39385046
88: Mendell JR, Proud C, Zaidman CM, et al. Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr Neurol 2024a;153:11-8. PMID 38306745
89: Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol 2020;77(9):1122-31. PMID 32539076
90: Mendell JR, Sahenk Z, Lehman K, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1/2a nonrandomized trial. Muscle Nerve 2024b;69(1):93-8. PMID 37577753
91: Mendell JR, Sheih PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol 2023;11:1167762. PMID 37497476
92: Mercuri E, Muntoni F, Osorio AN, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res 2020;9(5):341-60. PMID 31997646
93: Mercuri E, Pane M, Cicala G, Brogna C, Ciafaloni E. Detecting early signs in Duchenne muscular dystrophy: comprehensive review and diagnostic implications. Front Pediatr 2023;11:1276144. PMID 38027286
94: Mercuri E, Vilchez JJ, Boesplug-Tanguy O, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomized, double-blind, placebo controlled, phase 3 trial. Lancet Neurol 2024;23(8):393-403. PMID 3903004
95: Meryon E. On granular and fatty degeneration of the voluntary muscles. Med Chir Trans 1852;35:73. PMID 20895997
96: Minetti C, Chang HW, Medori R, et al. Dystrophin deficiency in young girls with sporadic myopathy and normal karyotype. Neurology 1991;41:1288-91. PMID 1714059
97: Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986;323:646-50. PMID 3773991
98: Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet 1984;66:17-40. PMID 6365739
99: Moxley RT, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy. (Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society). Neurology 2005;64:13-20. PMID 15642897
100: Mullard A. EMA reconsiders ‘read-through’ drug against Duchenne muscular dystrophy following appeal. Nat Biotechnol 2014;32(8):706. PMID 25101726
101: Natera-de Benito D, Aguilera-Albesa S, Costa-Comellas L, et al. Covid-19 in children with neuromuscular disorders. J Neurol 2021;268(9):3081-5. PMID 33387010
102: Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009;53(1):72-8. PMID 19167641
103: Pane M, Fanelli L, Mazzone ES, et al. Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscul Disord 2015;25(10):749-53. PMID 26248957
104: Papa R, Madia F, Bartolomeo D, et al. Genetic and early clinical manifestations of females heterozygous for Duchenne/Becker muscular dystrophy. Pediatr Neurol 2016;55:58-63. PMID 26718981
105: Pascual-Morena C, Luceron-Lucas-Torres M, Sequi-Dominguez I, Rodriguez-Gutierrez E, Patino-Cardona S, Sequi-Dominguez I. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a systemic review. Pediatr Drugs 2024;26(6):695-707. PMID 39331339
106: Petrof BJ. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol Cell Biochem 1998;179(1-2):111-23. PMID 9543354
107: Quinlivan R, Mahalekshmi D, Cruces F, Pietrusz A, Savvatis K. Clinical outcome of SARS-CoV-2 infection in 7 adults with Duchenne muscular dystrophy attending a specialist neuromuscular centre. Neuromuscular Disord 2021;31(7):603-6. PMID 34049776
108: Ricotti V, Mandy WP, Scotot M, et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol 2016;58(1):77-84. PMID 26365034
109: Riguzzi P, Sabbatini D, Fusto A, et al. Deep characterization of females with Duchenne muscular dystrophy mutations. J Neurol 2025;272(3):244. PMID 40035839
110: Roberts RG, Barby TF, Manners E, Bobrow M, Bentley DR. Direct detection of dystrophin gene rearrangements by analysis of dystrophin mRNA in peripheral blood lymphocytes. Am J Hum Genet 1991;49:298-310. PMID 1867192
111: Sarkozy A, Quinlivan R, Bourke JP, Ferlini A, ENMC 263rd Workshop Study Group. 263rd ENMC International Workshop: Focus on female carriers of dystrophinopathy: refining recommendations for prevention, diagnosis, surveillance, and treatment. Hoofddorp, The Netherlands, 13-15 May 2022. Neuromuscul Disord 2023;33(3):274-84. PMID 36804616
112: Scher DM, Mubarak SJ. Surgical prevention of foot deformity in patients with Duchenne muscular dystrophy. J Pediatr Orthop 2002;22(3):384-9. PMID 11961461
113: Schiava M, Lofra R, Bourke J, et al. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids. Eur J Neurol 2025;31(6):e16267. PMID 38556893
114: Scully MA, Farrell PM, Ciafaloni E, Griggs RC, Kwon JM. Cystic fibrosis newborn screening: a model for neuromuscular disease screening? Ann Neurol 2015;77(2):189-97. PMID 25425541
115: Servais L, Mercuri E, Straub V, et al. Long-term safety and efficacy data of Golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multi center, two-part, open-label, phase 1/2 trial. Nucleic Acid Ther 2022;32(1):29-39. PMID 34788571
116: Sheehan DW, Birnkrant DJ, Benditt JO, et al. Respiratory management of the patient with Duchenne muscular dystrophy. Pediatrics 2018;142(Suppler 2):S62-S71.** PMID 30275250
117: Shieh PB, Elfring G, Trifillis P, et al. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res 2021;10(18):1337-47. PMID 34693725
118: Simonds AK. Recent advances in respiratory care for neuromuscular disease. Chest 2006;130(6):1879-86. PMID 17167012
119: Subhan F, Zizzo MG, Serio R. Motor dysfunction of the gut in Duchenne muscular dystrophy : a review. Neurogastroenterol Motil 2024;36(8):e14804. PMID 38651673
120: Tandon A, Villa CR, Hor KN, et al. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. J Am Heart Assoc 2015;4(4). PMID 25814625
121: Taylor PJ, Betts GA, Maroulis S, et al. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS One 2010;5(1):e8803. PMID 20098710
122: Thangarajh M, Hendriksen J, McDermott MP, et al. Relationships between DMD mutations and neurodevelopment in dystrophinopathy. Neurology 2019;93(17):e1597-604. PMID 31594858
123: Thomas S, Conway KM, Fapo O, et al. Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000-2015. Muscle Nerve 2022;66(2):193-7. PMID 35312090
124: Trout J, Case LE, Clemens PR. A transition toolkit for Duchenne muscular dystrophy. Pediatrics 2018;142(Suppl 2):S110-7. PMID 30275255
125: Veerapandiyan A, Wagner KR, Apkon S, et al. The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic. Muscle Nerve 2020;60(1):41-5. PMID 32329920
126: Wagner KR. Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics 2008;5(4):583-91. PMID 19019310
127: Wagner KR, Kuntz, NL, Koenig E, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve 2021;64(3):285-92. PMID 34105177
128: Ward LM, Hadjiyannakis S, McMillan HJ, Noritz G, Weber DR. Bone health and osteoporosis management of the patient with Duchenne muscular dystrophy. Pediatrics 2018;142(Suppl 2):S34-S42.** PMID 30275247
129: Ward LM, Konji VN, Ma J. The management of osteoporosis in children. Osteoporosis Int 2016;27(7):2147-79. PMID 27125514
130: Watanabe N, Tone Y, Nagata T, et al. Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide. Mol Ther Nucleic Acids 2023;34:102034. PMID 37954955
131: Weber, DR, Hadijyannakis S, McMillan HJ, Nortiz G, Ward LM. Obesity and endocrine management of the patient with Duchenne muscular dystrophy. Pediatrics 2018;142(Suppl 2):S1-S4.** PMID 30275248
132: Yang JH, Kim KS, Lee GH, et al. Comparison of survival analysis between surgical and non-surgical treatments in Duchenne muscular dystrophy. Spine J 2020;(11):1840-949. PMID 32535073
133: Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 years) with Duchenne Muscular Dystrophy: 1-year interim results from Study SRP-9001-103 (ENDEAVOR). Ann Neurol 2023;94(5):955-68. PMID 37539981
134: Zhang G, Ludtke JJ, Thioudellet C, et al. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum Gene Ther 2004;15(8):770-82. PMID 15319034
135: Zhang G, Wooddell CI, Hegge JO, et al. Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection. Hum Gene Ther 2010;21(2):221-37. PMID 19788386

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Michele Gatheridge MD

Dr. Gatheridge of the University of Rochester Medical Center has no relevant financial relationships to disclose.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

Eric Hoffman PhD
Elena Pegoraro MD
Diana M Escolar PhD
Gyula Acsadi MD PhD
Emma Ciafaloni MD FAAN
Michael K Hehir MD

Patient Profile

Age range of presentation: 0 month to 18 years
Sex preponderance: male>female, >2:1
Heredity: heredity may be a factor

heredity typical

sex-linked recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Hereditary progressive muscular dystrophy: G71.0
ICD-11: Congenital muscular dystrophy: 8C70.6
OMIM: Duchenne muscular dystrophy: #310200

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Duchenne muscular dystrophy

Differential Diagnosis

Becker muscular dystrophy
severe childhood autosomal recessive muscular dystrophy
Duchenne-like muscular dystrophy
mutations of one of the four sarcoglycan genes
hepatitis
- elevated creatine kinase due to muscle activity (exercise)
- elevated creatine kinase due to metabolic myopathies
- elevated creatine kinase due to viral infection
- elevated creatine kinase due to muscle damage
- malignant hyperthermia

Also Relevant

Asymptomatic hyperCKemia
Becker muscular dystrophy
Limb-girdle muscular dystrophies
Management of chronic neuromuscular disease in children
Neuromuscular pathology: overview
- Prednisone
- Sleep and neuromuscular and spinal cord disorders

Clinical Categories

Neuromuscular Disorders

Patient Handouts

Web References

Guidelines

Alerts and Advisories

	• Duchenne muscular dystrophy affects approximately 1 in 5000 male births worldwide (27).
	• Ten percent of isolated cases of “idiopathic hyper-CKemic myopathy” in females are isolated cases of dystrophinopathy carriers.

Duchenne muscular dystrophy

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Other conditions to consider

Associated or underlying disorders

Diagnostic workup

Management

Table 1. FDA-Approved Exon Skipping Therapies

Table 2. FDA-Approved Gene Replacement Therapies

Special considerations

Pregnancy

Anesthesia

COVID-19

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Drug-induced myasthenic syndromes

Reducing body myopathy

Zilucoplan

Givinostat

Rozanolixizumab-noli

Efgartigimod alfa-fcab

Nusinersen

Efgartigimod alfa and hyaluronidase-qvfc

This is an article preview.
Start a Free Account
to access the full version.